Figure 4. Sequence-specific shRNAs targeting LMP1 inhibited tumor growth in vivo. A, Protocol of subcutaneous injection of xenograft tumor and plasmid treatment (by intravenous injection) procedure in nude mice. B, Growth curves of xenograft tumor volumes of the nude mice in three groups: G1: PBS 100 µL, G5: LMP1-shRNA1 plasmid (100 µL, 1.5 mg/kg), and G6: LMP1-shRNA2 plasmid (100 µL, 1.5 mg/kg). All groups were treated by caudal vein injection. C, Plasmids and nanomaterials were mixed in vitro in accordance with the requirements of the use of nanomaterials. PCR results show the nanomaterial and plasmid binding. D and E, Growth curves of tumor volumes of the nude mice in several groups: G2: Nano-LDH + shcontrol (100 µL, 1.5 mg/kg), G3: Nano-LDH + LMP1-shRNA1 (100 µL, 1.5 mg/kg), G4: Nano-LDH + LMP1-shRNA2 (100 µL, 1.5 mg/kg), G5: LMP1-shRNA1 plasmid (100 µL, 1.5 mg/kg), and G6: LMP1-shRNA2 plasmid (100 µL, 1.5 mg/kg). All groups were treated by caudal vein injection. F, Protocol of subcutaneous injection of xenograft tumor following the NPC-LMP1 antigen-specific T cells treatment (by intravenous injection) procedure in nude mice. G, Growth curves of xenograft tumor volumes of the nude mice in each group, including G7: CTL1 (NPC-LMP1-sh-control cells induced T cells) (200 µL, 2.5*10⁶ T cells), G8: CTL2 (NPC-LMP1-shRNA1 cells induced T cells) (200 µL, 2.5*10⁶ T cells), and G9: CTL3 (NPC-LMP1-shRNA2 cells induced T cells) (200 µL, 2.5*10⁶ T cells). Data are reported as means±SD (n=3). *P<0.05, **P<0.01, ***P<0.001 (Student's t-test). H, Schematic diagram of the mechanisms of specific-sequence shRNAs targeting LMP1 and inhibiting NPC growth.